Mycosis Fungoides: Pathophysiology and Emerging Therapies

Seminars in Oncology

Volumn 34, Issue SUPPL. 5, 2007, Pages

  Duvic, Madeleine ^a   Foss, Francine M ^b  

^a University of Texas Health Science Center at Houston   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BEXAROTENE; CARMUSTINE; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CPG 7909; CYCLOPHOSPHAMIDE; CYTARABINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FORODESINE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMIQUIMOD; IMMUCILLIN H; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISONE; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; SIPLIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT; ZANOLIMUMAB;

ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; FATIGUE; FLOW CYTOMETRY; HUMAN; IMMUNOPATHOGENESIS; LUNG EMBOLISM; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; OPTIMAL DRUG DOSE; PATHOPHYSIOLOGY; PHOTOTHERAPY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SKIN LYMPHOMA; SKIN MANIFESTATION; T CELL LYMPHOMA; T LYMPHOCYTE; TELANGIECTASIA; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

EID: 37049008056     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.11.006     Document Type: Article

References (56)

1. Lamberg S.I., and Bunn Jr. P.A. Proceeding of the workshop on cutaneous T-cell lymphomas (mycosis fungoides and Sézary syndromes). Cancer Treat Rep 63 (1979) 561-564
2. National Institutes of Health, National Cancer Institute. Mycosis Fungoides and the Sézary Syndrome Treatment. Available at:. http://www.nci.nih.gov/cancertopics/pdq/treatment/mycosisfungoides/HealthProfessional/page3 (accessed March 5, 2007)
3. Alibert J.L.M. Description des maladies de la peau observees a l'hôpital St Louis. Barrois L'aine et Fils 1 (1806) 413-446
4. Bazin PAE: Maladies de la peau observees a l'hôpital St Louis, 1876.
5. Willemze R., Jaffe E.S., Berg G., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105 (2005) 3768-3785
6. Besnier E., and Hallopeau H. On the erythrodermia of mycosis fungoides. J Cutan Genito Urin Dis 10 (1892) 453
7. Bunn Jr. P.A., and Lamberg S.I. Report of the Committee on Staging and Classification of Cutaneous T-cell Lymphomas. Cancer Treat Rep 63 (1979) 725-728
8. Schechter G.P., Sausville E.A., Fischmann A.B., et al. Evaluation of circulating malignant cells provides prognostic information in cutaneous T-cell lymphoma. Blood 69 (1987) 841-849
9. Kim Y.H., Liu H.L., Mraz-Gernhard S., et al. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: Clinical prognostic factors and risk for disease progression. Arch Dermatol 39 (2003) 857-866
10. Tan R.S., Butterworth C.M., McLaughlin H., et al. Mycosis fungoides: A disease of antigen persistence. Br J Dermatol 91 (1974) 607-616
11. Bromley S.K., Burack K.G., Johnson K., et al. The immunological synapse. Annu Rev Immunol 19 (2001) 375-396
12. Olsen E.A., and Bunn Jr. P.A. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9 (1995) 1089-1107
13. Drummer R., Kohl O., Gillisson J., et al. Peripheral blood mononuclear cells in non-leukemic cutaneous-cell lymphoma patients: Reduced proliferation and preferential secretion of a T helper 2 like cytokine pattern on stimulation. Arch Dermatol 129 (1993) 433-436
14. Wood G.S., and Greenberg H.L. Diagnosis, staging, and monitoring of cutaneous T-cell lymphoma. Dermatol Ther 16 (2003) 269-275
15. Xiao N.L., Hazarika P., Zhang C., et al. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in Mycosis fungoides: A potential mechanism of tumor immune escape?. Clin Cancer Res 7 (2001) 2682-2692
16. Trautinger F., Knobler R., Willemze R., et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42 (2006) 1014-1030
17. Breneman D., Duvic M., Kuzel T., et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 138 (2002) 325-332
18. Do J.H., McLaughlin S.S., and Gaspari A.A. Topical imiquimod therapy for cutaneous T-cell lymphoma. Skinmed 2 (2003) 316-318
19. Querfeld C., Lakshmi V.N., Rosen S.T., et al. Bexarotene in the treatment of cutaneous T-cell lymphoma. Expert Opin Pharmacother 7 (2006) 1-9
20. Duvic M., Talpur R., Ni X., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 (2007) 31-39
21. Lundin J., Hagberg H., Repp R., et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood 101 (2003) 4267-4272
22. Kim Y.H., Duvic M., and Obitz E. Clinical efficacy of zanolimumab (HuMax-CD4): Two phase II studies in refractory cutaneous T-cell lymphoma. Blood 109 (2007) 4655-4662
23. O'Mahony D., Morris J.C., Moses L., et al. Phase I trial of siplizumab in CD2-positive lymphoproliferative disease. Blood 106 suppl 1 (2005) 937a (abstr 3353)
24. Forero-Torres A., Bernstein S.H., Gopal A., et al. SGN-30 (Anti-CD30 mAb) has a single-agent response rate of 21% in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL). Blood 108 (2006) 768a (abstr 2718)
25. Rook A.H., Zaki M.H., Wysocka M., et al. The role for interleukin-12 therapy of cutaneous T-cell lymphoma. Ann NY Acad Sci 941 (2001) 177-184
26. Rook A.H., Wood G.S., and Yoo E.K. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94 (1999) 902-908
27. Foss F.M., Bacha P., Osann K.E., et al. Biological correlates of acute hypersensitivity with DAB(389) IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: Decreased frequency and severity with steroid premedication. Clin Lymphoma 1 (2001) 298-302
28. Talpur R., Jones D.M., Alencar A.J., et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 126 (2006) 575-583
29. Edelson R.L. Cutaneous T cell lymphoma: The helping hand of dendritic cells. Ann NY Acad Sci 941 (2001) 1-11
30. Drummer R. Emerging drugs in cutaneous T-cell lymphoma. Expert Opin Emerg Drugs 10 (2005) 1-12
31. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92 (2000) 1210-1216
32. Marks P., Rifkind R.A., Richon V.M., et al. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1 (2001) 194-202
33. Piekarz R.L., Robey R., Sandor V., et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report. Blood 98 (2001) 2865-2868
34. Zhang C., Richon V., Ni X., et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. J Invest Dermatol 125 (2005) 1045-1052
35. Olsen E.A., Kim Y.H., Kuzel T.M., et al. A phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (2007) 3109-3115
36. Piekarz R.L., Frye R., Turner M., et al. Completion of the first cohort of patients with cutaneous T-cell lymphoma enrolled on a phase II trial of depsipeptide. Blood 106 (2005) 71a (abstr 231)
37. Prince H.M., George D.J., Johnstone R., et al. LBH589, a novel histone deacetylase inhibitor (HDACi), treatment of patients with cutaneous T-cell lymphoma (CTLC): Changes in skin gene expression profiles related to clinical response following therapy. Proc Am Soc Clin Oncol 24 (2006) 422s (abstr 7501)
38. Parks Jr. R.E., and Aggarwal R.P. In: Boyer P.D. (Ed). The Enzymes. Ed 3 vol 7 (1972), Academic Press, New York 483-514
39. Giblett E.R., Ammann A.J., Wara D.W., et al. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1 (1975) 1010-1013
40. Markert M.L. Purine nucleoside phosphorylase deficiency. Immunodefic Rev 3 (1991) 45-81
41. Bantia S., Ananth S.L., Parker C.D., et al. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777. Int Immunopharmacol 3 (2003) 879-887
42. Ni X., Zhang C., Talpur R., et al. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol 124 (2005) 741-750
43. Reed C.J. Apoptosis and cancer: strategies for integrating cell death. Semin Hematol 37 (2000) 9-16
44. Bantia S., and Kilpatrick J.M. Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Curr Opin Drug Dis Dev 7 (2004) 243-247
45. Miles R.W., Tyler P.C., Furneaux R.H., et al. One-third-the-sites transition-state inhibitors to purine nucleoside phosphorylase. Biochemistry 37 (1998) 8615-8621
46. Bantia S., Miller P.J., Parker C.D., et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)-A novel potent and orally active immunosuppressive agent. Int Immunopharmacol 1 (2001) 1199-1210
47. Kicska G.A., Long L., Horig H., et al. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase selectively inhibits human T lymphocytes. Proc Nat Acad Sci U S A 98 (2001) 4593-4598
48. Bantia S., Ananth S.L., Parker C.D., et al. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777. Int Immunopharmacol 3 (2003) 879-887
49. Bantia S., Miller P.J., Parker C.D., et al. Comparison of in vivo efficacy of BCX-1777 and cyclosporine in xenogeneic graft-vs.-host disease: The role of dGTP in antiproliferative action of BCX-1777. Int Immunopharmacol 2 (2002) 913-923
50. Duvic M., Foss F., Olsen E.A., et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma. Blood 104 (2004) 683a (abstr 2491)
51. Duvic M., Apisarnthanarax N., Cohen D.S., et al. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 49 (2003) 35-49
52. Furman R.R., Gandhi V.V., Bennett J.C., et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-cell acute lymphoblastic leukemia. Blood 104 (2004) 750a (abstr 2743)
53. Furman R.R., Iosava G., Isola L., et al. Forodesine (Fodosine), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients (phase III study). Blood 106 (2005) 259a (abstr 881)
54. Isola L., Furman R.R., Gandhi V., et al. Antileukemic activity and pharmacodynamics of intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, in phase I/II trials in patients with advanced T-cell malignancies. Blood 104 (2004) 208b (abstr 4501)
55. Duvic M., Ziari S., Olsen E.A., et al. Phase 1-2 multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma. Proc Am Soc Clin Oncol 22 (2004) 613a (abstr 6733)
56. Duvic M., Forero-Torres A., Foss F., et al. Oral forodesine (BCX-1777) is clinically active in refractory cutaneous T-cell lymphoma: Results of a phase I/II study. Proc Am Soc Hematol 108 (2006) 698a (abstr 2467)